{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000116","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.447674+00:00","generated_at":"2026-05-31T12:54:36.972664+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA","bullets":["Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.","GAAP diluted EPS $0.77 vs $0.25 YoY; non-GAAP diluted EPS $0.84 vs $0.31.","FDA accepted sNDA for cabozantinib in advanced NET; target action date April 3, 2025.","Earned $150M milestone from Ipsen; completed $450M buyback; new $500M buyback authorized through 2025.","Discontinued XB002 development; plans to initiate phase 3 for zanzalintinib in NET."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000116","json":"https://secwatch.observer/filing/0000939767-24-000116.json","markdown":"https://secwatch.observer/filing/0000939767-24-000116.md","text":"https://secwatch.observer/filing/0000939767-24-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000116/0000939767-24-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000116/exel-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:54:36.972664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}